Board Director of the Asian Pharmacometrics Network (APN).
Member of Pfizer Global Clinical Pharmacology Standards Board.
She has been committed to Pharmacometrics since joined Pfizer (China) R&D Center in 2012, and won individual Pfizer Quality Award in 2019.
During her career in Pfizer, she’s been supporting drug development and regulatory submissions across therapeutic areas including Paxlovid, Ibrance, Lorlatinib, Tofacitinib, Bosutinib, and published more than 10 SCI articles.
She supported authoring and updating Pfizer internal Clinical Pharmacology Guidances, Standards, process Booklet, etc.
She’s been serving as SME for key Clinical pharmacology platform within Pfizer.
She also contributed to the development and maintenance of platform & tools for Pfizer Pharmacometrics workflow/automation.
辉瑞（中国）研发中心，临床药理学部，定量药理学副总监。
亚洲定量药理互联（Asian Pharmacometrics Network， APN）委员会成员。
辉瑞全球临床药理学标准委员会成员。
自2012年加入辉瑞（中国）研发中心以来，一直致力于定量药理学领域，并于2019年荣获辉瑞个人“杰出质量”奖。
在辉瑞从业期间，支持了跨疾病领域的多个药物的研发和注册申报，包括奈玛特韦片/利托那韦片组合（Paxlovid）、爱博斯（Ibrance）、劳拉替尼 （Lorlatinib）、托法替尼 （Tofacitinib）、博苏替尼 （Bosutinib）等，并发表SCI文章10余篇。
参与了辉瑞内部临床药理指导原则、数据标准、流程指南的撰写和更新工作。
担任辉瑞临床药理工具平台领域专家（SME）。
参与支持辉瑞定量药理工作流和自动化工作平台及工具的开发和维护。